Arca
Skip to content
Tools
Tools

Ventricular tachycardia

Drug research and approvals for ventricular tachycardia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 87 studies of ventricular tachycardia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 2 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 87
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 87 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 3

Phase 2 5

Phase 1 or earlier 2

How its trials ended

389 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 101 whose ending is known, 39% met their primary endpoint, 2% missed it and 59% stopped early.

  • Completed, result not reported13033%
  • Ongoing10226%
  • Status unknown5614%
  • Met its primary endpoint3910%
  • Stopped: other or unclear287%
  • Stopped: enrollment or feasibility185%
  • Stopped: sponsor or business decision82%
  • Stopped: lack of efficacy41%
  • Missed its primary endpoint21%
  • Stopped: funding21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 27, 2025A phase 1b, multicenter, open-label, dose finding study to investigate the safety and tolerability of a single intravenous dose of SGT-501 in patients with…SGT-501 (RAAV8-DES-CASQ2)Solid BiosciencesPending
Dec 18, 2024A phase 2, double-blind, repeat-dose, placebo-controlled crossover study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…CRD-4730Cardurion PharmaceuticalsOngoing
Dec 2, 2022A phase 2a, investigator and subject blinded, sponsor unblinded, placebo-controlled, clinical study to evaluate the safety, tolerability, pharmacokinetics, and…CRD-4730Cardurion PharmaceuticalsClosed
Jul 5, 2018Pretreatment with atropine to reduce exercise-triggered ventricular ectopy in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT)AtropineBC CHILDREN's HOSPITAL HEART CENTREPending

FDA orphan designations

Approved first, then open designations, newest first
Jul 2, 2009So-AqueousFor use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of…AltaThera Pharmaceuticals LLCApproved
Aug 3, 1995CordaroneFor initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular…Wyeth-Ayerst LaboratoriesApproved
Mar 30, 2026(S)-(3-bromo-4-(trifluoromethyl)phenyl)(2-(5-methyl-[1,2,4]t…Treatment of catecholaminergic polymorphic ventricular tachycardiaAgiana PharmaceuticalsDesignated
May 5, 20204-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl…Treatment of Catecholaminergic Polymorphic Ventricular TachycardiaRyCarma Therapeutics, Inc.Designated
Oct 2, 2014Adeno-associated viral vector serotype 8 containing the…Treatment of catecholaminergic polymorphic ventricular tachycardiaSolid Biosciences Inc.Designated
Aug 17, 1993AmiodaroneTreatment of incessant ventricular tachycardia.Academic Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.